Arena Pharmaceuticals Inc
ARNA
ARNA was delisted on the 10th of March, 2022.
177 hedge funds and large institutions have $1.53B invested in Arena Pharmaceuticals Inc in 2018 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 58 increasing their positions, 50 reducing their positions, and 22 closing their positions.
82% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 22
16% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 50
11% more funds holding
Funds holding: 160 → 177 (+17)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
17% less capital invested
Capital invested by funds: $1.85B → $1.53B (-$319M)
23% less call options, than puts
Call options by funds: $11.8M | Put options by funds: $15.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$25.3M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$19.6M |
| 3 |
Primecap Management
Pasadena,
California
|
+$18.7M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$15.1M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$11.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$34M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$26.8M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$17.3M |
| 4 |
State Street
Boston,
Massachusetts
|
-$15.3M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$12.1M |
ARNA Hedge Fund Activity: Q4 2018 in Review
177 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Arena Pharmaceuticals Inc (ARNA) for Q4 2018, worth a combined $1.53B — down 17% from $1.85B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new ARNA positions and 22 closed out — a net gain of 18 holders — while 58 added to existing stakes and 50 trimmed.
The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $25.3M. The largest seller was Fidelity Investments, cutting an estimated $34M.
- 177 institutional investors held Arena Pharmaceuticals Inc (ARNA) as of Q4 2018, up from 160 in Q3 2018.
- Funds reported $1.53B of Arena Pharmaceuticals Inc stock for Q4 2018, down 17% quarter-over-quarter.
- 40 funds opened new Arena Pharmaceuticals Inc positions in Q4 2018 and 22 closed out, a net change of +18 holders.
- The largest Arena Pharmaceuticals Inc buyer in Q4 2018 was Rubric Capital Management (New York), an estimated $25.3M added.
- The largest Arena Pharmaceuticals Inc seller in Q4 2018 was Fidelity Investments, an estimated $34M sold.
Based on aggregated 13F filings for Q4 2018.